ONtrack

Urine assay for the screening of prostate cancer

The current screening is based on the measurement of the biomarker PSA in the blood of men to select those who are at risk of having prostate cancer. Unfortunately, PSA has very high false positives, resulting in a high number of unnecessary prostate biopsies, as up to 75% of men who are tested, result having no tumor.  Our urine assay is a companion test to PSA and is able to reduce its false positives by half, potentially sparing 500.000 men/year in the USA alone this invasive medical procedure.
Logo